The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Exploiting Synthetic Lethality for the Therapy of ABC Diffuse Large B Cell Lymphoma
Open accessAbstract
Summary Knowledge of oncogenic mutations can inspire therapeutic strategies that are synthetically lethal, affecting cancer cells while sparing normal cells. Lenalidomide is an active agent in the activated B-cell-like (ABC) subtype of diffuse large B cell lymphoma (DLBCL), but its mechanism of action is unknown. Lenalidomide kills ABC DLBCL cells by augmenting interferon β (IFNβ) production, owing to the oncogenic MYD88 mutations in these lymphomas. In a cereblon-dependent fashion, lenalidomide downregulates IRF4 and SPIB, transcription factors that together prevent IFNβ production by repressing IRF7 and also amplify pro-survival NF-κB signaling by transactivating CARD11. Blockade of B cell receptor (BCR) signaling using the BTK inhibitor ibrutinib also downregulates IRF4 and consequently synergizes with lenalidomide in killing ABC DLBCLs, suggesting attractive therapeutic strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
Alizadeh, A. A., Eisen, M. B., Davis, R. E., Ma, C., Lossos, I. S., Rosenwald, A., Boldrick, J. C., Sabet, H., Tran, T., Yu, X., et al. (2000) · Nature · doi:10.1038/35000501 · Cited by 9,925
Self-citationHOW CELLS RESPOND TO INTERFERONS
Stark, G. R., Kerr, I. M., Williams, B. R. G., Silverman, R. H., & Schreiber, R. D. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.227 · Cited by 3,932
Rosenwald, A., Wright, G., Chan, W. C., Connors, J. M., Campo, E., Fisher, R. I., Gascoyne, R. D., Muller-Hermelink, H. K., Smeland, E. B., Giltnane, J. M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012914 · Cited by 3,829
Self-citationIRF-7 is the master regulator of type-I interferon-dependent immune responses
Honda, K., Yanai, H., Negishi, H., Asagiri, M., Sato, M., Mizutani, T., Shimada, N., Ohba, Y., Takaoka, A., Yoshida, N., et al. (2005) · Nature · doi:10.1038/nature03464 · Cited by 2,245
Identification of a Primary Target of Thalidomide Teratogenicity
Ito, T., Ando, H., Suzuki, T., Ogura, T., Hotta, K., Imamura, Y., Yamaguchi, Y., & Handa, H. (2010) · Science · doi:10.1126/science.1177319 · Cited by 2,136
Stromal Gene Signatures in Large-B-Cell Lymphomas
Lenz, G., Wright, G., Dave, S. S., Xiao, W., Powell, J., Zhao, H., Xu, W., Tan, B., Goldschmidt, N., Iqbal, J., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802885 · Cited by 1,808
Self-citationChronic active B-cell-receptor signalling in diffuse large B-cell lymphoma
Davis, R. E., Ngo, V. N., Lenz, G., Tolar, P., Young, R. M., Romesser, P. B., Kohlhammer, H., Lamy, L., Zhao, H., Yang, Y., et al. (2010) · Nature · doi:10.1038/nature08638 · Cited by 1,643
Self-citationOncogenically active MYD88 mutations in human lymphoma
Ngo, V. N., Young, R. M., Schmitz, R., Jhavar, S., Xiao, W., Lim, K.-H., Kohlhammer, H., Xu, W., Yang, Y., Zhao, H., et al. (2011) · Nature · doi:10.1038/nature09671 · Cited by 1,512
Self-citationThe Concept of Synthetic Lethality in the Context of Anticancer Therapy
Kaelin, W. G. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1691 · Cited by 1,379
Rosenwald, A., Wright, G., Leroy, K., Yu, X., Gaulard, P., Gascoyne, R. D., Chan, W. C., Zhao, T., Haioun, C., Greiner, T. C., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20031074 · Cited by 1,101
Self-citationIs NF-κB a good target for cancer therapy? Hopes and pitfalls
Baud, V., & Karin, M. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2781 · Cited by 1,061
Shaffer, A. L., Shapiro-Shelef, M., Iwakoshi, N. N., Lee, A.-H., Qian, S.-B., Zhao, H., Yu, X., Yang, L., Tan, B. K., Rosenwald, A., et al. (2004) · Immunity · doi:10.1016/j.immuni.2004.06.010 · Cited by 1,054
Self-citationDavis, R. E., Brown, K. D., Siebenlist, U., & Staudt, L. M. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.12.1861 · Cited by 1,051
Self-citationMarie, I. (1998) · The EMBO Journal · doi:10.1093/emboj/17.22.6660 · Cited by 1,049
Wright, G., Tan, B., Rosenwald, A., Hurt, E. H., Wiestner, A., & Staudt, L. M. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1732008100 · Cited by 1,040
Self-citationMolecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways
Lenz, G., Wright, G. W., Emre, N. C. T., Kohlhammer, H., Dave, S. S., Davis, R. E., Carty, S., Lam, L. T., Shaffer, A. L., Xiao, W., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804295105 · Cited by 995
Self-citationOncogenic CARD11 Mutations in Human Diffuse Large B Cell Lymphoma
Lenz, G., Davis, R. E., Ngo, V. N., Lam, L., George, T. C., Wright, G. W., Dave, S. S., Zhao, H., Xu, W., Rosenwald, A., et al. (2008) · Science · doi:10.1126/science.1153629 · Cited by 867
Self-citationTranscription factor IRF4 controls plasma cell differentiation and class-switch recombination
Klein, U., Casola, S., Cattoretti, G., Shen, Q., Lia, M., Mo, T., Ludwig, T., Rajewsky, K., & Dalla-Favera, R. (2006) · Nature Immunology · doi:10.1038/ni1357 · Cited by 801
Inhibiting NF-κB activation by small molecules as a therapeutic strategy
Gupta, S. C., Sundaram, C., Reuter, S., & Aggarwal, B. B. (2010) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2010.05.004 · Cited by 762
Friedberg, J. W., Sharman, J., Sweetenham, J., Johnston, P. B., Vose, J. M., LaCasce, A., Schaefer-Cutillo, J., De Vos, S., Sinha, R., Leonard, J. P., et al. (2010) · Blood · doi:10.1182/blood-2009-08-236471 · Cited by 747
IRF4 addiction in multiple myeloma
Shaffer, A. L., Emre, N. C. T., Lamy, L., Ngo, V. N., Wright, G., Xiao, W., Powell, J., Dave, S., Yu, X., Zhao, H., et al. (2008) · Nature · doi:10.1038/nature07064 · Cited by 730
Self-citationCereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide
Zhu, Y. X., Braggio, E., Shi, C.-X., Bruins, L. A., Schmidt, J. E., Van Wier, S., Chang, X.-B., Bjorklund, C. C., Fonseca, R., Bergsagel, P. L., et al. (2011) · Blood · doi:10.1182/blood-2011-05-356063 · Cited by 607
A loss-of-function RNA interference screen for molecular targets in cancer
Ngo, V. N., Davis, R. E., Lamy, L., Yu, X., Zhao, H., Lenz, G., Lam, L. T., Dave, S., Yang, L., Powell, J., et al. (2006) · Nature · doi:10.1038/nature04687 · Cited by 605
Self-citationSciammas, R., Shaffer, A. L., Schatz, J. H., Zhao, H., Staudt, L. M., & Singh, H. (2006) · Immunity · doi:10.1016/j.immuni.2006.07.009 · Cited by 571
Self-citationPositive feedback regulation of type I IFN genes by the IFN‐inducible transcription factor IRF‐7
Sato, M., Hata, N., Asagiri, M., Nakaya, T., Taniguchi, T., & Tanaka, N. (1998) · FEBS Letters · doi:10.1016/s0014-5793(98)01514-2 · Cited by 553
Hoellenriegel, J., Meadows, S. A., Sivina, M., Wierda, W. G., Kantarjian, H., Keating, M. J., Giese, N., O'Brien, S., Yu, A., Miller, L. L., et al. (2011) · Blood · doi:10.1182/blood-2011-05-352492 · Cited by 549
Herman, S. E. M., Gordon, A. L., Wagner, A. J., Heerema, N. A., Zhao, W., Flynn, J. M., Jones, J., Andritsos, L., Puri, K. D., Lannutti, B. J., et al. (2010) · Blood · doi:10.1182/blood-2010-02-271171 · Cited by 543
Dunleavy, K., Pittaluga, S., Czuczman, M. S., Dave, S. S., Wright, G., Grant, N., Shovlin, M., Jaffe, E. S., Janik, J. E., Staudt, L. M., et al. (2009) · Blood · doi:10.1182/blood-2009-01-199679 · Cited by 497
Self-citationPip, a novel IRF family member, is a lymphoid-specific, PU.1-dependent transcriptional activator.
Eisenbeis, C. F., Singh, H., & Storb, U. (1995) · Genes & Development · doi:10.1101/gad.9.11.1377 · Cited by 447 · cited 2×
“IRF4 binds to a 10-base-pair motif, termed the ETS/IRF composite element (EICE) (Kanno et al., 2005; Marecki and Fenton, 2000), in conjunction with one of two highly homologous ETS-family transcription factors, PU.1 and SPIB (Brass et al., 1996; Eisenbeis et al., 1995; Shaffer et al., 1997).”
BackgroundTamura, T., Tailor, P., Yamaoka, K., Kong, H. J., Tsujimura, H., O’Shea, J. J., Singh, H., & Ozato, K. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.5.2573 · Cited by 423
CARMA1, BCL-10 and MALT1 in lymphocyte development and activation
Thome, M. (2004) · Nature Reviews Immunology · doi:10.1038/nri1352 · Cited by 391
Saito, M., Gao, J., Basso, K., Kitagawa, Y., Smith, P. M., Bhagat, G., Pernis, A., Pasqualucci, L., & Dalla-Favera, R. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.08.011 · Cited by 387
Lam, L. T., Wright, G., Davis, R. E., Lenz, G., Farinha, P., Dang, L., Chan, J. W., Rosenwald, A., Gascoyne, R. D., & Staudt, L. M. (2008) · Blood · doi:10.1182/blood-2007-09-111948 · Cited by 353
Self-citationMilhollen, M. A., Traore, T., Adams-Duffy, J., Thomas, M. P., Berger, A. J., Dang, L., Dick, L. R., Garnsey, J. J., Koenig, E., Langston, S. P., et al. (2010) · Blood · doi:10.1182/blood-2010-03-272567 · Cited by 323
Self-citationLam, L. T., Davis, R. E., Pierce, J., Hepperle, M. E., Xu, Y., Foley, M. H., Nong, Y., Wen, D., Adams, J., Dang, L., et al. (2005) · PubMed · Cited by 312
Self-citationHernandez‐Ilizaliturri, F. J., Deeb, G., Zinzani, P. L., Pileri, S. A., Malik, F., Macon, W. R., Goy, A., Witzig, T. E., & Czuczman, M. S. (2011) · Cancer · doi:10.1002/cncr.26135 · Cited by 304
Brass, A. L., Kehrli, E., Eisenbeis, C. F., Storb, U., & Singh, H. (1996) · Genes & Development · doi:10.1101/gad.10.18.2335 · Cited by 242 · cited 2×
“IRF4 binds to a 10-base-pair motif, termed the ETS/IRF composite element (EICE) (Kanno et al., 2005; Marecki and Fenton, 2000), in conjunction with one of two highly homologous ETS-family transcription factors, PU.1 and SPIB (Brass et al., 1996; Eisenbeis et al., 1995; Shaffer et al., 1997).”
BackgroundAntigen Receptor Signaling to NF- B via CARMA1, BCL10, and MALT1
Thome, M., Charton, J. E., Pelzer, C., & Hailfinger, S. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a003004 · Cited by 241
Lam, L. T., Davis, R. E., Pierce, J., Hepperle, M., Xu, Y., Hottelet, M., Nong, Y., Wen, D., Adams, J., Dang, L., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.28.11.1 · Cited by 229
Self-citationA library of gene expression signatures to illuminate normal and pathological lymphoid biology
Shaffer, A. L., Wright, G., Yang, L., Powell, J., Ngo, V., Lamy, L., Lam, L. T., Davis, R. E., & Staudt, L. M. (2006) · Immunological Reviews · doi:10.1111/j.0105-2896.2006.00373.x · Cited by 228
Self-citationGreco, W. R., Park, H. S., & Rustum, Y. M. (1990) · PubMed · Cited by 219
Brass, A. L., Zhu, A. Q., & Singh, H. (1999) · The EMBO Journal · doi:10.1093/emboj/18.4.977 · Cited by 204 · cited 2×
“1 fusion functions as a sequence-specific transcriptional repressor (Brass et al., 1999).”
BackgroundLenz, G., Nagel, I., Siebert, R., Roschke, A. V., Sanger, W., Wright, G. W., Dave, S. S., Tan, B., Zhao, H., Rosenwald, A., et al. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20062041 · Cited by 195
Self-citationIRF4: Immunity. Malignancy! Therapy?
Shaffer, A. L., Emre, N. C. T., Romesser, P. B., & Staudt, L. M. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1845 · Cited by 189
Self-citationLopez‐Girona, A., Heintel, D., Zhang, L., Mendy, D., Gaidarova, S., Brady, H., Bartlett, J. B., Schafer, P. H., Schreder, M., Bolomsky, A., et al. (2011) · British Journal of Haematology · doi:10.1111/j.1365-2141.2011.08689.x · Cited by 181
Crystal structure of PU. 1/IRF-4/DNA ternary complex
Escalante, C. R., Brass, A. L., Pongubala, J. M. R., Shatova, E., Shen, L., Singh, H., & Aggarwal, A. K. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00703-7 · Cited by 154 · cited 1×
“A crystal structure of the mouse IRF4 and PU.1 DNA binding domains bound to an EICE motif allowed us to model the human IRF4-SPIB interaction (Escalante et al., 2002a, 2002b).”
MethodSchotte, R., Rissoan, M., Bendriss‐Vermare, N., Bridon, J., Duhen, T. M., Weijer, K. C., Brière, F., & Spits, H. (2003) · Blood · doi:10.1182/blood-2002-02-0438 · Cited by 129
Immune cell-specific amplification of interferon signaling by the IRF-4/8-PU. 1 complex
Kanno, Y., Levi, B.-Z., Tamura, T., & Ozato, K. (2005) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2005.25.770 · Cited by 128
Lehtonen, A., Veckman, V., Nikula, T., Lahesmaa, R., Kinnunen, L., Matikainen, S., & Julkunen, I. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.10.6570 · Cited by 120
Li, S., Pal, R., Monaghan, S. A., Schafer, P. H., Ouyang, H., Mapara, M. Y., Galson, D. L., & Lentzsch, S. (2011) · Blood · doi:10.1182/blood-2010-10-314278 · Cited by 94
Immunomodulatory derivatives induce PU.1 down-regulation, myeloid maturation arrest, and neutropenia
Pal, R., Monaghan, S. A., Hassett, A. C., Mapara, M. Y., Schafer, P. H., Roodman, G. D., Ragni, M. V., Moscinski, L. C., List, A. F., & Lentzsch, S. (2009) · Blood · doi:10.1182/blood-2009-05-221077 · Cited by 91
Shaffer, A. L., Peng, A., & Schlissel, M. S. (1997) · Immunity · doi:10.1016/s1074-7613(00)80420-3 · Cited by 82
Self-citationPU.1/Interferon Regulatory Factor Interactions; Mechanisms of Transcriptional Regulation
Marecki, S., & Fenton, M. J. (2000) · Cell Biochemistry and Biophysics · doi:10.1385/cbb:33:2:127 · Cited by 74
INVOLVEMENT OF TRAIL/TRAIL-R INTERACTION IN IFN-α-INDUCED APOPTOSIS OF DAUDI B LYMPHOMA CELLS
Oshima, K., Yanase, N., Ibukiyama, C., Yamashina, A., Kayagaki, N., Yagita∥, H., & Mizuguchi, J. (2001) · Cytokine · doi:10.1006/cyto.2001.0873 · Cited by 47
Recent advances of IMiDs in cancer therapy
Li, S., Gill, N. K., & Lentzsch, S. (2010) · Current Opinion in Oncology · doi:10.1097/cco.0b013e32833d752c · Cited by 35
Crystallization and characterization of PU.1/IRF-4/DNA ternary complex
Escalante, C. R., Shen, L., Escalante, M. C., Brass, A. L., Edwards, T. A., Singh, H., & Aggarwal, A. K. (2002) · Journal of Structural Biology · doi:10.1016/s1047-8477(02)00514-2 · Cited by 18
Ucur, E., Mattern, J., Wenger, T., Okouoyo, S., Schroth, A., Debatin, K., & Herr, I. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6601407 · Cited by 12
Cited by
Genetics and pathogenesis of diffuse large B-cell lymphoma
Schmitz, R., Wright, G. W., Huang, D. W., Johnson, C. A., Phelan, J. D., Wang, J. Q., Roulland, S., Kasbekar, M., Young, R. M., Shaffer, A. L., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801445 · Cited by 2,241
Self-citationLenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells
Krönke, J., Udeshi, N. D., Narla, A., Grauman, P., Hurst, S. N., McConkey, M., Svinkina, T., Heckl, D., Comer, E., Li, X., et al. (2014) · Science · doi:10.1126/science.1244851 · Cited by 1,879
The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
Lu, G., Middleton, R. E., Sun, H., Naniong, M., Ott, C. J., Mitsiades, C. S., Wong, K.-K., Bradner, J. E., & Kaelin, W. G. (2014) · Science · doi:10.1126/science.1244917 · Cited by 1,583
Type I interferons in anticancer immunity
Zitvogel, L., Galluzzi, L., Kepp, O., Smyth, M. J., & Kroemer, G. (2015) · Nature Reviews Immunology · doi:10.1038/nri3845 · Cited by 1,305
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
Wilson, W. H., Young, R. M., Schmitz, R., Yang, Y., Pittaluga, S., Wright, G., Lih, C.-J., Williams, P. M., Shaffer, A. L., Gerecitano, J., et al. (2015) · Nature Medicine · doi:10.1038/nm.3884 · Cited by 1,113
Self-citation
Metadata
- Authors
- Yang, Y., Shaffer, A. L., Emre, N. C. T., Ceribelli, M., Zhang, M., Wright, G., Xiao, W., Powell, J., Platig, J., Kohlhammer, H., Young, R. M., Zhao, H., Yang, Y., Xu, W., Buggy, J. J., Balasubramanian, S., Mathews, L. A., Shinn, P., Guha, R., Ferrer, M., Thomas, C., Waldmann, T. A., & Staudt, L. M.
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2012-06
- Volume
- 21
- Issue
- 6
- Pages
- 723-737
- ISSN
- 1535-6108 (ISSN-L)
- OpenAlex
- W1970400561
- Cited by
- 521
- References
- 57
- FWCI
- 36.79
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.